Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI).

Sumanta K. Pal,Javier Puente,Daniel Yick Chin Heng,Hilary Glen,Piotr Koralewski,Daniil Stroyakovskiy,Boris Alekseev,Francis Parnis,Daniel Castellano,Tudor Ciuleanu,Jae-Lyun Lee,Kaisa Sunela,Karen OHara,Terri A. Binder,Lixian Peng,Alan D. Smith,Sun Young Rha

Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI).

2021

Sumanta K. Pal
Javier Puente
Daniel Yick Chin Heng
Hilary Glen
Piotr Koralewski
Daniil Stroyakovskiy
Boris Alekseev
Francis Parnis
Daniel Castellano
Tudor Ciuleanu
Jae-Lyun Lee
Kaisa Sunela
Karen OHara
Terri A. Binder
Lixian Peng
Alan D. Smith
Sun Young Rha

307Background: LEN 18 mg + EVE 5 mg is approved for advanced RCC following anti-angiogenic therapy. Study 218 was a phase II study evaluating LEN 14 mg vs LEN 18 mg, both in combination with EVE 5 ...

Keywords:

Lenvatinib
Oncology
in patient
Renal cell carcinoma
Immune checkpoint
Everolimus
Medicine
Internal medicine
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations